Bris­tol My­ers Squibb catch­es the SHP2 wave in a new col­lab­o­ra­tion deal with Bridge­Bio

4 years ago
Deals

Busi­ness­es and schools can man­date the use of Covid-19 vac­cines un­der EUAs, DOJ says

4 years ago
FDA+
Coronavirus

BioN­Tech is spear­head­ing an mR­NA vac­cine de­vel­op­ment pro­gram for malar­ia, with a tech trans­fer planned for Africa

4 years ago
R&D
Manufacturing

How one start­up fore­told the neu­ro­science re­nais­sance af­ter '50 years of shit­show'

4 years ago
R&D
In Focus

What will Lu­mi­ra Ven­tures do with $220M? Stay out of the com­fort zone and off the beat­en biotech path

4 years ago
Financing

No­var­tis part­ner Ar­tios bags megaround to dri­ve clin­i­cal work on DNA dam­age re­pair fac­tors

4 years ago
Financing

House com­mit­tee seeks more from FDA on in­spec­tion back­log, when to restart work on for­eign sites

4 years ago
FDA+

Let the games be­gin: No­vo Nordisk takes the gold in Cowen's 'R&D pen­tathlon'

4 years ago
R&D

Chi­nese re­searcher — and for­mer 'fugi­tive' — re­turns home af­ter DOJ moves to drop a spate of cas­es

4 years ago
People
China

Bay­er poach­es newest ear­ly R&D head from Roche; Glax­o­SmithK­line earns ex­pand­ed nod for Shin­grix

4 years ago
News Briefing

Bob Nelsen's ARCH adds FDA, biode­fense ex­per­tise with ap­point­ment of Lu­ciana Bo­rio

4 years ago
People

Shelling out $5B+, PerkinElmer pays the big bucks for an­ti­body and reagent play­er

4 years ago
Deals
Outsourcing

Eye­ing quick ap­proval, Ab­b­Vie of­fers a close-up on their pres­by­opia drug da­ta

4 years ago
R&D

The clock is tick­ing for Iterum af­ter FDA hands down CRL for Pfiz­er castoff an­tibi­ot­ic

4 years ago
R&D
FDA+

De­nali slips as a snap­shot of ear­ly da­ta rais­es some trou­bling ques­tions on its pi­o­neer­ing blood-brain bar­ri­er neu­ro ...

4 years ago
R&D

An­oth­er one bites the dust: Bris­tol My­ers Squibb pulls 'dan­gling' ac­cel­er­at­ed ap­proval for Op­di­vo in liv­er can­cer

4 years ago
FDA+

J&J’s Rem­i­cade — the poster child for how to block biosim­i­lars — fi­nal­ly set­tles Pfiz­er suit

4 years ago
Pharma

Covid-19 roundup: Fau­ci says multi­bil­lion-dol­lar pro­gram could curb fu­ture pan­demics; Japan­ese drug­mak­er spices up ...

4 years ago
Coronavirus

Small, strug­gling biotech winds up with a 3X los­er as an­oth­er PhI­II of its lead drug col­laps­es

4 years ago
R&D

FDA un­sur­pris­ing­ly brings down the ham­mer on In­cyte's PD-1 — draw­ing a line for fu­ture ac­cel­er­at­ed ap­provals

4 years ago
FDA+

No­var­tis reshuf­fles its wild cards; Tough sell for Bio­gen? Googling pro­teins; Ken Fra­zier's new gig; and more

4 years ago
Weekly

Google's Deep­Mind opens its pro­tein data­base to sci­ence — po­ten­tial­ly crack­ing drug R&D wide open

4 years ago
Discovery

Mod­er­na es­tab­lish­es pub­lic health-fo­cused char­i­ty; FDA ap­proves As­traZeneca di­a­betes drug for pe­di­atric use

4 years ago
News Briefing

Three biotechs price hefty IPOs just be­fore the week­end, while a fourth and a SPAC seek spots on Wall Street

4 years ago
Financing
First page Previous page 661662663664665666667 Next page Last page
A service from the Financial Times